InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Discover the complete record of transactions filed by Doyle Anthony, Chief Financial Officer. Director active across 1 companies, notably Biocryst Pharmaceuticals INC. Cumulatively, 6 disclosures have been recorded. Total volume traded: €783k. The latest transaction was filed on 14 December 2021 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations6 total
075,000 shares0
Common Stock
SEC:0001127602-22-001456·
075,000 shares0
Common Stock
SEC:0001127602-22-001456:0·
0115,000 shares0
Common Stock
SEC:0001127602-21-031121·
0115,000 shares0
Common Stock
SEC:0001127602-21-031121:0·
€391,40235,258 shares@ €11.10110.024% mcap100.0% of flow
Common Stock
SEC:0001171843-21-008176·
Ideal exit: 20 Aug 2022 (T+270)
€391,40235,258 shares@ €11.10110.024% mcap50.0% of flow
Common Stock
SEC:0001171843-21-008176:0·
Ideal exit: 20 Aug 2022 (T+270)
6 of 6 declarations
About Doyle Anthony
Anthony Doyle is the Chief Financial Officer of Biocryst Pharmaceuticals Inc. He oversees the financial management of the company, bringing his expertise in finance and strategy. His role is essential for ensuring the profitability and growth of the organization.
